Logo
x

Search category

Subscribe Now

Proposed Biosimilar

Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

  • July 20, 2021
Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

  • July 20, 2021
Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

  • July 16, 2021
Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

  • July 16, 2021
Gan Lee Presents P-I Results of Proposed Biosimilar Insulins Aspart- Lispro and Glargine at ADA 2021

Gan Lee Presents P-I Results of Proposed Biosimilar Insulins Aspart- Lispro and Glargine at ADA 2021

  • July 5, 2021
Gan Lee Presents P-I Results of Proposed Biosimilar Insulins Aspart- Lispro and Glargine at ADA 2021

Gan Lee Presents P-I Results of Proposed Biosimilar Insulins Aspart- Lispro and Glargine at ADA 2021

  • July 5, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.